As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
COVID-19 and impact on peer review
Featured article: Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?
Despite the theoretical concerns of increased ACE2 expression by Renin-Angiotensin-Aldosterone system (RAS) blockade, there is no evidence that RAS inhibitors are harmful during COVID-19 infection and have in fact been shown to be beneficial in animal studies. Therefore, it is recommended to maintain RAS blockade during the current corona virus pandemic.
Clinical Hypertension is a continuation of the Journal of the Korean Society of Hypertension, formerly published by IB Planning Co. All content from Journal of the Korean Society of Hypertension is freely available at KoreaMed.
We are pleased to announce that all articles published in Clinical Hypertension journal are included in PubMed, PubMed Central and DOAJ.
Prof Wook-Jin Chung, Editor-in-Chief
Prof Chung is Professor of Medicine at the Gachon University College of Medicine in Incheon, Korea. He gained his MD degree at Yonsei University College of Medicine in Seoul, Korea and was awarded a PhD in medical science by Yonsei University in 2009. He then joined the faculty of Gachon University and currently serves as Professor of Medicine. His research interests primarily focus on pulmonary hypertension, heart failure and cardiac imaging including innovative device developments. His approach has deepened the understanding of pathophysiology leading to translational deep phenotyping and therapeutic options in hypertension, pulmonary hypertension and heart failure.
2018 Korean Society of Hypertension guidelines for the management of hypertension
In response to the growing need for revision of the hypertension treatment guideline, the Guideline Committee of the Korean Society of Hypertension have written their updated guidelines for the management of hypertension. The articles cover epidemiology, diagnosis and treatment and treatment of hypertension, and hypertension in special situations.
KSH annual congress
The 52nd Scientific Meeting of the Korean Society of Hypertension is to be held on 7th-8th August 2020 in BEXCO, Busan, Korea.
The theme of this conference is “ Stronger Collaboration for Better Control of Hypertension.”
We look forward to your support and participation.
Aims and scope
Clinical Hypertension is a peer-reviewed, open access journal that aims to publish in all areas of hypertension and vascular disorders. We aim to ensure the widest possible dissemination of research throughout the hypertension community.
The journal focuses on areas within peripheral vascular diseases, vascular biology, cellular and molecular biology, clinical hypertension, epidemiology, nephrology, endocrinology, neuroscience, pharmacology, genetics, pediatric hypertension and basic science.
Clinical Hypertension is a continuation of the Korean journal, Journal of the Korean Society of Hypertension.
Official journal of
Clinical Hypertension is the official journal of the Korean Society of Hypertension.
The Society is currently covering all publication costs so there are no article processing charges for authors.
Annual Journal Metrics
41 days to first decision for reviewed manuscripts only
31 days to first decision for all manuscripts
103 days from submission to acceptance
47 days from acceptance to publication
54 Altmetric Mentions